Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 12 of 18 · 826 articles
Based on the title and source metadata, this appears to be a patient story related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from msn.com.
Personal stories from public figures can help normalize living with Crohn’s and highlight practical issues many patients face, like diet and effects on growth. Fans or people newly diagnosed may find reassurance and tips...
Frequent routine colonoscopies after Crohn's surgery are invasive and burdensome. Using fecal calprotectin for regular monitoring could reduce unnecessary colonoscopies and detect recurrence earlier when inflammation is...
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from springermedicine.com.
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
A CE mark under the EU IVDR means a new non-invasive test aimed at identifying dietary triggers for people with UC or Crohn’s may become available in Europe. Tests like this could affect how some patients and clinicians...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original...
Based on the title and source metadata, this appears to be an event or fundraiser related to Crohn's disease and Community and awareness. The original article is from msn.com.
A new CE-marked food-intolerance diagnostic could give people with Crohn’s or UC a non-invasive tool to explore dietary triggers alongside clinical care. Regulatory certification means the products met EU safety and...
A predictive model for temporary stoma could influence surgical planning for people with Crohn’s disease, helping tailor decisions and expectations around intestinal resection.
Cure8 could only read part of this source from appliedclinicaltrialsonline.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory...
Community and charity programs can provide emotional relief and memorable experiences for children with Crohn’s disease and their families. Stories like this show resources beyond medical care that can improve quality of...
Based on the title and source metadata, this appears to be a patient story related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from msn.com.
Cure8 could only read part of this source from bodyslam.net, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness.
Researchers and clinicians studying Crohn’s disease want to understand whether distinct patient subgroups exist that could affect outcomes or responses. Identifying subpopulations can guide future research into...
Detecting neoplasia early is a central goal of IBD surveillance; this study suggests virtual chromoendoscopy may find more lesions than dye or white light in real-world practice, which could influence how surveillance is...
A new FDA‑approved biosimilar to ustekinumab is now available in the U.S., which may increase treatment options and lower out‑of‑pocket costs for people with Crohn’s disease or ulcerative colitis. The article highlights...
A new FDA‑approved ustekinumab biosimilar (YESINTEK) is now available in the US for Crohn’s disease and ulcerative colitis, which may increase treatment options and lower costs. Coverage and copay support at launch could...
Cure8 could only read part of this source from ajmc.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Complications.
The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...
This study suggests a Crohn disease exclusion diet (with partial enteral nutrition) helped some pediatric patients reach steroid-free clinical remission and lowered fecal calprotectin, measures important for disease...
Older adults with IBD have higher cardiovascular risk; medication choice may affect cardiovascular outcomes. This study suggests ustekinumab users had fewer deaths and some cardiac events than vedolizumab users, which...
Cure8 could only read part of this source from devdiscourse.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.
The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.
Cure8 found this source from clevelandjewishnews.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Crohn's disease, and Community and awareness. Open the original article for...
This reports Phase 2b trial results for duvakitug showing improved remission and endoscopic response versus placebo in UC and CD—early evidence that could lead to a new treatment option if later trials confirm benefit...
Cure8 could only read part of this source from money.rediff.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Ulcerative colitis, and Ustekinumab.
Changes in the therapeutics market can affect availability, pricing, and access to Crohn’s treatments. Growth in biosimilars and new drug approvals may influence what options become more widely available.
Cure8 found this source from financialexpress.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biosimilars. Open the original article for the full...
The study explores whether larger spleen size might play a causal role in the risk of ulcerative colitis or Crohn’s disease, using genetic data to reduce confounding. If a causal link exists, spleen volume could be a...
If approved, Tremfya SC induction could provide a fully subcutaneous induction and maintenance option for people with moderately to severely active ulcerative colitis, which may be more convenient than IV induction.
New Phase 2b data were presented for duvakitug, an investigational antibody for UC and Crohn’s disease; people with IBD may see this as a potential future treatment option if later trials are positive. The report focuses...
Cure8 found this source from rollingout.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the...
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
Cure8 found this source from newsmax.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. Open the original article for the full details.
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the...
People with Crohn's disease who have an ileostomy need reliable, noninvasive tools to monitor for postoperative small-bowel inflammation. This study suggests fecal calprotectin measured from ileostomy output may help...
First-person stories from public figures can reduce stigma, show that people with Crohn's can continue their careers, and highlight practical coping strategies like diet, routines, and treatment adherence. Knowing about...
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
Local fundraising events raise money and visibility for people living with Crohn’s and colitis and can connect patients, families, and supporters. Participating or volunteering supports the charity and can offer social...
The study suggests a surgical change—removing the mesentery during Crohn’s operations—may significantly reduce early recurrence in the intestinal lining, which could mean fewer repeat surgeries and hospital readmissions...
Cure8 could only read part of this source from crainscleveland.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Community and...
This study maps what researchers have been publishing about Crohn's disease in children over the past decade, highlighting major topics, influential papers, and active authors/institutions.
Some people with Crohn’s have ongoing GI symptoms despite little visible inflammation. This study suggests the gut microbiome—particularly sulfur-producing bacteria—may be a reason, and diet could be a potential target...
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...
This is early-stage research about combining antibody targets (α4β7 and TL1A) for IBD; if validated in humans, combination biologics could offer improved effectiveness or dosing convenience.
